GlassScriptPhysician profile
Jonathan B Croopnick
NPI 1598871360
$5,823.63
in general payments reported to CMS, 2019-2025
37 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $231 · 2021: $696 · 2022: $1,912 · 2023: $1,929 · 2024: $360 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,839 · Education: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,838.53 |
| Education | $641.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $1,356.96 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $1,226.25 | 2020-2025 | Myrisk, Precisetumor |
| Astellas Pharma US INC | $681.37 | 2021-2023 | Xtandi |
| E.R. Squibb & Sons, L.L.C. | $218.77 | 2019-2025 | Opdivo |
| Janssen Biotech, INC. | $191.20 | 2022-2024 | Erleada, Darzalex, Imbruvica |
| Pharmacyclics LLC, An Abbvie Company | $172.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $163.52 | 2019-2023 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $153.72 | 2021-2023 | Lynparza, Enhertu |
| Celgene Corporation | $150.52 | 2021-2024 | Reblozyl, Opdualag |
| Array Biopharma INC | $126.52 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Janssen Pharmaceuticals, INC | $124.39 | 2019-2022 | |
| Amgen INC. | $114.02 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Seagen INC. | $106.60 | 2019-2023 | Padcev |
| Pfizer INC. | $105.23 | 2020-2023 | |
| Eisai INC. | $103.78 | 2019-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $91.76 | 2019-2020 | |
| Abbvie INC. | $82.95 | 2021 | |
| Taiho Oncology, INC. | $76.53 | 2023-2025 | |
| Glaxosmithkline, LLC. | $71.41 | 2021-2023 | Ojjaara, Jemperli, Zejula |
| Csl Behring | $59.92 | 2023-2024 | Hemgenix |
| Genentech USA, INC. | $53.98 | 2019 | |
| Daiichi Sankyo INC. | $47.46 | 2020-2023 | Injectafer |
| Acrotech Biopharma INC. | $34.33 | 2022-2023 | Beleodaq |
| Exelixis INC. | $31.19 | 2021 | |
| Organon LLC | $29.52 | 2023 | Ontruzant |
| Welch Allyn | $29.46 | 2021 | |
| Karyopharm Therapeutics INC. | $28.48 | 2022 | |
| Mirati Therapeutics, INC. | $24.98 | 2023 | Krazati |
| Amag Pharmaceuticals, INC. | $24.26 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.91 | 2023 | Gilotrif |
| Novartis Pharmaceuticals Corporation | $21.33 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $21.29 | 2019 | |
| Progenics Pharmaceuticals, INC. | $18.03 | 2023 | Pylarify |
| Cti Biopharma Corp. | $17.74 | 2023 | Vonjo |
| Ipsen Biopharmaceuticals, INC | $14.83 | 2019 | |
| Adc Therapeutics America, INC. | $14.13 | 2023 | |
| Lilly USA, LLC | $11.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Croopnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.